RU2014124032A - Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с - Google Patents

Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с Download PDF

Info

Publication number
RU2014124032A
RU2014124032A RU2014124032A RU2014124032A RU2014124032A RU 2014124032 A RU2014124032 A RU 2014124032A RU 2014124032 A RU2014124032 A RU 2014124032A RU 2014124032 A RU2014124032 A RU 2014124032A RU 2014124032 A RU2014124032 A RU 2014124032A
Authority
RU
Russia
Prior art keywords
subject
hcv
protease inhibitor
indicated
hepatitis
Prior art date
Application number
RU2014124032A
Other languages
English (en)
Other versions
RU2606759C2 (ru
Inventor
Рима БЕНЕЙД
Лоран ЭССЬЮ
Мерсидита Т. НАВАРРО
Джузеппе ПАЛЕРМО
Бриджит РИЛИ-ГИЛЛИС
Юнхун ЧЖУ
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2014124032A publication Critical patent/RU2014124032A/ru
Application granted granted Critical
Publication of RU2606759C2 publication Critical patent/RU2606759C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Способ прогнозирования восприимчивости человека, инфицированного вирусом гепатита С (HCV), к терапии пэгинтерфероном альфа-2a, рибавирином и противовирусным агентом прямого действия, включающий:обеспечение образца от указанного человека и идентификацию нуклеотида, присутствующего в однонуклеотидном полиморфизме rs12148487, где наличие по меньшей мере одной аллели A в rs12148487 у указанного субъекта указывает на высокую вероятность быстрого вирусологического ответа в течение двух недель (RVR2), достигнутого указанным субъектом в ответ на указанное лечение, по сравнению с субъектом, который имеет две G-аллели, присутствующие в rs12148487.2. Способ по п. 1, где указанный субъект инфицирован HCV с генотипом 1 или генотипом 4.3. Способ по п. 2, где указанный противовирусный агент прямого действия представляет собой ингибитор протеазы HCV.4. Способ по п. 3, где указанный ингибитор протеазы HCV выбран из группы, состоящей из данопревира, боцепревира, телапревира, ванипревира, MK-5172, TMC-435 и нарлапревира.5. Способ по п. 4, где указанный ингибитор протеазы HCV представляет собой данопревир.

Claims (5)

1. Способ прогнозирования восприимчивости человека, инфицированного вирусом гепатита С (HCV), к терапии пэгинтерфероном альфа-2a, рибавирином и противовирусным агентом прямого действия, включающий:
обеспечение образца от указанного человека и идентификацию нуклеотида, присутствующего в однонуклеотидном полиморфизме rs12148487, где наличие по меньшей мере одной аллели A в rs12148487 у указанного субъекта указывает на высокую вероятность быстрого вирусологического ответа в течение двух недель (RVR2), достигнутого указанным субъектом в ответ на указанное лечение, по сравнению с субъектом, который имеет две G-аллели, присутствующие в rs12148487.
2. Способ по п. 1, где указанный субъект инфицирован HCV с генотипом 1 или генотипом 4.
3. Способ по п. 2, где указанный противовирусный агент прямого действия представляет собой ингибитор протеазы HCV.
4. Способ по п. 3, где указанный ингибитор протеазы HCV выбран из группы, состоящей из данопревира, боцепревира, телапревира, ванипревира, MK-5172, TMC-435 и нарлапревира.
5. Способ по п. 4, где указанный ингибитор протеазы HCV представляет собой данопревир.
RU2014124032A 2011-11-28 2012-11-26 Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с RU2606759C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564032P 2011-11-28 2011-11-28
US61/564,032 2011-11-28
PCT/EP2012/073554 WO2013079424A1 (en) 2011-11-28 2012-11-26 A single nucleotide polymorphism on chromosome 15 that predicts hcv treatment responses

Publications (2)

Publication Number Publication Date
RU2014124032A true RU2014124032A (ru) 2016-01-27
RU2606759C2 RU2606759C2 (ru) 2017-01-10

Family

ID=47221425

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014124032A RU2606759C2 (ru) 2011-11-28 2012-11-26 Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с

Country Status (12)

Country Link
US (1) US20130137084A1 (ru)
EP (1) EP2785875B1 (ru)
JP (1) JP5834146B2 (ru)
KR (1) KR101656158B1 (ru)
CN (1) CN103987862B (ru)
BR (1) BR112014012886A2 (ru)
CA (1) CA2850904C (ru)
ES (1) ES2573500T3 (ru)
HK (1) HK1200876A1 (ru)
MX (1) MX349879B (ru)
RU (1) RU2606759C2 (ru)
WO (1) WO2013079424A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
CN105463084B (zh) * 2015-12-11 2019-04-12 上海新培晶医学检验所有限公司 一种检测白介素28b三个snp位点基因型的试剂盒及其检测方法
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
RU2287825C1 (ru) * 2005-07-25 2006-11-20 Александр Валентинович Ягода СПОСОБ ПРОГНОЗИРОВАНИЯ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С ПРЕПАРАТАМИ ИНТЕРФЕРОНА-α
CA2735439A1 (en) * 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analysis of hcv genotypes
EP2379745A1 (en) * 2008-12-18 2011-10-26 F. Hoffmann-La Roche AG Biomarkers for hcv treatment response
MX2012005528A (es) * 2009-11-14 2012-06-12 Hoffmann La Roche Biomarcadores para pronosticar rapida respuesta a tratamiento hcv.
CA2795911A1 (en) * 2010-04-13 2011-10-20 F. Hoffmann-La Roche Ag Single nucleotide polymorphisms that predict hcv treatment outcomes
BR112012026124A2 (pt) * 2010-04-13 2016-11-22 Hoffmann La Roche previsão de resposta virológica precoce no tratamento de hcv
IT1399564B1 (it) * 2010-04-16 2013-04-19 Metzeler Automotive Profile Guarnizione di tenuta per un autoveicolo, e procedimento per la sua fabbricazione
US20120196272A1 (en) * 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment

Also Published As

Publication number Publication date
KR101656158B1 (ko) 2016-09-08
KR20140088168A (ko) 2014-07-09
JP2014533108A (ja) 2014-12-11
EP2785875B1 (en) 2016-04-27
CN103987862A (zh) 2014-08-13
CN103987862B (zh) 2016-05-25
RU2606759C2 (ru) 2017-01-10
MX2014006185A (es) 2014-07-10
CA2850904C (en) 2018-10-02
EP2785875A1 (en) 2014-10-08
ES2573500T3 (es) 2016-06-08
JP5834146B2 (ja) 2015-12-16
MX349879B (es) 2017-08-16
CA2850904A1 (en) 2013-06-06
HK1200876A1 (en) 2015-08-14
WO2013079424A1 (en) 2013-06-06
BR112014012886A2 (pt) 2017-06-13
US20130137084A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
RU2014124032A (ru) Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с
RU2013109732A (ru) Прогноз кинетики вируса гепатита с при лечении, исключающем интерферон
Raghwani et al. Exceptional heterogeneity in viral evolutionary dynamics characterises chronic hepatitis C virus infection
WO2010025380A3 (en) Analysis of hcv genotypes
Akamatsu et al. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A
BRPI0512745A (pt) métodos de genotipagem e de caracterizar um agente e kit
WO2019051257A3 (en) Methods for treating hepatitis b infections
RU2012145776A (ru) Прогнозирование раннего вирусологического ответа при лечении заражения вирусом гепатита с
RU2012100987A (ru) Способ прогнозирования отслойки хориона и плаценты на ранних сроках беременности на основании определения полиморфизма генов ингибитора активатора плазминогена i типа (pai-1)
ES2674053T3 (es) Diagnóstico de paraplejias espásticas hereditarias (HPS) a través de la identificación de una mutación en el gen o proteína ZFYVE26
NZ599373A (en) Biomarkers for predicting rapid response to hcv treatment
MX2009008788A (es) Poliformismos de serpine1 son predictivos de respuesta a administracion de proteina c activada y riesgo de muerte.
RU2012145777A (ru) Однонуклеотидные полиморфизмы для прогнозирования результатов лечения заражения вирусом гепатита с
WO2009021121A3 (en) Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
AR104348A1 (es) Polimorfismos de un solo nucleótido seleccionados que son predictivos de respuestas al acetato de glatirámero
Ghonaim et al. Toll-like Receptor 7 Expression and Gene Polymorphism in Patients with Hepatitis C and Hepatocellular Carcinoma
RU2012145062A (ru) Биочип для генотипирования ряда маркеров гаплогрупп y-хромосомы человека: m130 (c), м145 (de)
Barbera et al. IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication
Walworth Cross-sectional Assessment of 1500 Clinical Samples Submitted for HCV NS3/4A Protease Inhibitor Drug Resistance Testing in the US
RU2012140862A (ru) Способ прогнозирования риска возникновения переломов
Helaly et al. Sequence heterogeneity in the core and NS5A region of hepatitis c virus (hcv) and il-28b polymorphisms in predicting treatment response among chronic HCV genotype 4 infected Egyptian patients
RU2011109775A (ru) Способ прогнозирования риска возникновения ишемического инсульта у больных гипертонической болезнью
CN105018570A (zh) 用于检测IFITM3-rs12252基因多态性的Taqman荧光定量RT-PCR引物和探针
RU2012116999A (ru) Способ прогнозирования риска развития параноидной шизофрении
RU2013104659A (ru) Способ прогнозирования повышенного риска спонтанного внутримозгового кровоизлияния у монголоидов с артериальной гипертензией

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201127